Selected Grants
A Phase¿3, randomized, open-label study of belantamab mafodotin, administered in combination with lenalidomide, and dexamethasone (BRd) versus daratumumab, lenalidomide, and dexamethasone (DRd) in participants with newly diagnosed multiple myeloma
Clinical TrialPrincipal Investigator · Awarded by GlaxoSmithKline Research and Development Limited · 2025 - 2030External Relationships
- GSK
- Takeda Oncology
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.